Abcellera Biologics Inc
F:8QQ

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
F:8QQ
Watchlist
Price: 2.49 EUR -7.78% Market Closed
Market Cap: €732.2m

Wall Street
Price Targets

8QQ Price Targets Summary
Abcellera Biologics Inc

Wall Street analysts forecast 8QQ stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 8QQ is 8.9 EUR with a low forecast of 6.27 EUR and a high forecast of 14.9 EUR.

Lowest
Price Target
6.27 EUR
152% Upside
Average
Price Target
8.9 EUR
257% Upside
Highest
Price Target
14.9 EUR
498% Upside
Abcellera Biologics Inc Competitors:
Price Targets
TES
Tesmec SpA
-13% Downside
GLSI
Greenwich Lifesciences Inc
77% Upside
TMO
Thermo Fisher Scientific Inc
34% Upside

Revenue
Forecast

20% / Year
Past Growth
50% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
20% / Year
Past Growth
50% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

For the last 5 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 20%. The projected CAGR for the next 4 years is 50%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 8QQ's stock price target?
Price Target
8.9 EUR

According to Wall Street analysts, the average 1-year price target for 8QQ is 8.9 EUR with a low forecast of 6.27 EUR and a high forecast of 14.9 EUR.

What is Abcellera Biologics Inc's Revenue forecast?
Projected CAGR
50%

For the last 5 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 20%. The projected CAGR for the next 4 years is 50%.

Back to Top